Nexavar dosing in renal cancer patients in "real-life" setting (NEXST)
This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.
- Age >/= 18 years - Diagnosis of renal cell carcinoma - Failure of prior therapy with interferon-alfa (IFN) or interleukine-2 (IL-2) or disqualified from therapy with IFN/IL-2 - Patients in whom the oncologist has decide to start therapy with sorafenib.
-Synonymous with contraindications to Nexavar.
Many Locations, Poland
E-mail: [email protected]
Phone: Not Available
Nexavar dose evaluation study in patients with advanced renal cell carcinoma